A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers
A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Precision medicine therapies require identification of unique molecular cancer characteristics. Hexokinase (HK) activity has been proposed as a therapeutic target; however, different hexokinase isoforms have not been well characterized as alternative targets. While HK2 is highly expressed in the majority of cancers, cancer subtypes with differentia...
Alternative Titles
Full title
A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_440363d204aa4ccf82544f27f7fe42b8
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_440363d204aa4ccf82544f27f7fe42b8
Other Identifiers
ISSN
2049-3002
E-ISSN
2049-3002
DOI
10.1186/s40170-018-0181-8
